Clinical Trials Logo

Clinical Trial Summary

Nasal continuous positive airway pressure (CPAP) and Nasal High Flow (NHF) therapy are two primary therapies for the treatment of respiratory distress in newborns. However, a considerable number of infants, who are initially treated with CPAP and NHF, will develop worsening respiratory failure and eventually require intubation for mechanical ventilation and the administration of surfactant. Infants who fail noninvasive respiratory therapy may suffer the consequences of delayed intubation, surfactant administration and other adverse outcomes. The most challenging decisions in the management of respiratory distress after birth is to decide when to move from a noninvasive respiratory support to invasive mechanical ventilation and give surfactant to decrease pulmonary damage and improve outcomes. There are no clinically adequate predictors of early CPAP failure at the time of admission to the neonatal intensive care unit. Many measurements have been investigated for their ability to predict CPAP failure in infants such as fraction of inspired oxygen (FiO2), partial pressure of oxygen (PaO2), PaO2/FiO2 and the stable micro bubble test as soon as possible after birth. Roca and colleagues first established the ROX index to predict the success of NHF therapy in adults with pneumonia. The ROX index combines three common measurements: FiO2, peripheral oxygen saturation (SpO2) and respiratory rate. Combining the ROX values with the change in the respiratory rate and FiO2 can indicate whether escalation is required. It was proposed that XY plot of the key components of ROX may show the direction of changes in vector form. The investigators hypothesized that the ROX index and ROX vector can be used for predicting the failure of CPAP and NHF in neonates.

Clinical Trial Description

The objective is to explore the usefulness of ROX index to predict treatment failure of NHF and CPAP therapies in neonates. The primary outcome is treatment failure within 72 h after start of the therapy with NHF or CPAP Treatment failure criteria is reached once an infant is receiving maximal therapy for their treatment (NHF 8 L/min) or CPAP 7 cm H2O plus at least one of: 1. Sustained increase in oxygen requirement ≥50% to maintain peripheral oxygen saturation (SpO2) 90%-94%. 2. Any infant requiring urgent intubation and the subsequent mechanical ventilation, as determined by the physician. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05036161
Study type Observational
Source Erebouni Medical Center
Contact Pavel Mazmanyan, Prof
Phone +374 10 47 23 40
Email [email protected]
Status Recruiting
Start date September 6, 2021
Completion date December 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT02988336 - TMHT - New Method of Difficult Intubation Prediction N/A
Recruiting NCT03649594 - Risk Stratification Post TAVI Using TEG
Completed NCT03437837 - Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China
Completed NCT02957084 - Anatomic Features of the Neck and Preoperative Tests as Predictive Markers of Difficult Laryngoscopy N/A
Active, not recruiting NCT04439487 - Thyromental Height Test as a New Method for Prediction of Difficult Intubation in Obese Patients
Completed NCT04101734 - TMHT - Difficult Intubation Prediction Using Double Lumen Video Tubes
Completed NCT03647371 - TMHT - Difficult Intubation Prediction Using Videolaryngoscopy N/A
Completed NCT03180060 - Meta-Analysis of Stress Myocardial Perfusion Imaging N/A
Recruiting NCT03608995 - Diagnostic Tests in the Context of Threatened Preterm Labour N/A
Completed NCT03354546 - Development and Validation of a Preoperative Frailty Index Using Health Administrative Data N/A